Alphabet’s life sciences arm, Verily, is partnering with the digital pathology platform Lumea to improve the objectivity and efficiency of prostate cancer diagnosis, prognosis, and therapy selection.
Verily developed AI systems for digital pathology to reduce variability and maximize insights from biopsy tissue samples, according to a March 16 news release.
The collaboration aims to accomplish the following:
1. Enable Verily to validate its Gleason algorithms for prostate cancer using Lumea’s platform and extensive database of pathology cases.
2. Integrate Verily’s algorithms into Lumea’s digital pathology platform. Pathologists will then have access to Verily’s AI to help identify and grade prostate cancer within their digital workflow.
Read more on Becker’s Hospital Review.
Learn how comprehensive digital pathology that starts with the patient can help improve the quality of your practice, reduce costs, and scale your business here.
